삼성바이오로직스&nbsp;주가가&nbsp;장&nbsp;초반&nbsp;오르고&nbsp;있다.<br /> <br /> 삼성바이오로직스가&nbsp;이달&nbsp;안에&nbsp;다국적제약회사&nbsp;모더나의&nbsp;코로나19&nbsp;백신&nbsp;시제품을&nbsp;생산할&nbsp;것으로&nbsp;전망되고&nbsp;있다.<br /> &nbsp; <figure class="image" style="float:right;margin-right:0px; margin-left:15px; margin-top:30px; "><img alt="삼성바이오로직스 주가 초반 상승, 모더나 백신 시제품 곧 생산" height="200" class='lazyload' data-src="https://www.businesspost.co.kr/news/photo/202006/20200615122023_20054.jpg" width="300" /> <figcaption><table width=320><tr><td align='left' style='margin:0; padding:0px 0px; color:#306f7f; font-size:12px; font-family:verdana; letter-spacing:-0.1em; line-height:160%; table-layout: fixed; width:180px;'>▲ 삼성바이오로직스 로고.</td></tr></table></figcaption> </figure> <br /> 17일&nbsp;오전&nbsp;10시32분&nbsp;기준&nbsp;삼성바이오로직스&nbsp;주가는&nbsp;직전&nbsp;거래일보다&nbsp;2.85%(2만8천&nbsp;원)&nbsp;오른&nbsp;101만1천&nbsp;원에&nbsp;거래되고있다.<br /> <br /> 삼성바이오로직스는&nbsp;5월&nbsp;모더나와&nbsp;코로나19 mRNA(메신저리보핵산)&nbsp;백신인&nbsp;mRNA-1273&nbsp;수억&nbsp;회분을&nbsp;위탁생산하는계약을&nbsp;맺었다.<br /> <br /> 삼성바이오로직스는&nbsp;3분기부터&nbsp;모더나&nbsp;백신의&nbsp;완제공정을&nbsp;맡기로&nbsp;했다.&nbsp;모더나로부터&nbsp;백신&nbsp;원액을&nbsp;공급받아&nbsp;유리병(바이알)의&nbsp;무균충전,&nbsp;라벨링,&nbsp;포장&nbsp;등을&nbsp;담당한다.<br /> <br /> 삼성바이오로직스가&nbsp;본격적으로&nbsp;모더나의&nbsp;코로나19&nbsp;백신&nbsp;위탁생산에&nbsp;돌입하면&nbsp;삼성바이오로직스의&nbsp;실적&nbsp;증가폭이&nbsp;확대될 수 있다.&nbsp;<br /> <br /> 권덕철&nbsp;보건복지부&nbsp;장관은&nbsp;5일&nbsp;정부서울청사에서&nbsp;열린&nbsp;브리핑을&nbsp;통해&nbsp;&quot;삼성바이오로직스는&nbsp;8월&nbsp;말부터&nbsp;모더나의&nbsp;코로나19 mRNA(메신저&nbsp;리보핵산)&nbsp;백신의&nbsp;완제품&nbsp;시생산을&nbsp;기획하고&nbsp;있다&quot;며&nbsp;&quot;정부는&nbsp;원활한&nbsp;생산이&nbsp;이뤄지도록&nbsp;적극&nbsp;지원하겠다&quot;고&nbsp;말했다.&nbsp;[비즈니스포스트 박안나 기자]